FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)

On Thursday, the U.S. Food and Drug Administration (FDA) approved Merck & Co Inc.’s (NYSE:MRK) LIPFENDRA (enlicitide) as an adjunct to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).

The condition is characterized by the presence of high levels of cholesterol in the blood, particularly “bad” LDL cholesterol.

The company said the treatment is the first FDA-approved oral PCSK9 inhibitor and is designed as a once-daily pill to lower LDL cholesterol.

Read Next

Trading Ideas